Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.071
Sell
RSI(14)
41.550
Neutral
STOCH(KDJ)(9,3,3)
30.508
Sell
ATR(14)
1.583
High Vlolatility
CCI(14)
-73.524
Neutral
Williams %R
83.857
Oversold
TRIX(12,20)
-0.276
Sell
StochRSI(14)
0.000
Sell
XOMA Royalty Corp
XOMA24.860USD
-0.060-0.24%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
306.03MMarket Cap
30.63P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of XOMA Royalty Corp
Currency: USD Updated: 2026-02-06Key Insights
XOMA Royalty Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 36 out of 76 in the Media & Publishing industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 64.50.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
XOMA Royalty Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
XOMA Royalty Corp Highlights
StrengthsRisks
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 372.66% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 28.49M.
Overvalued
The company’s latest PE is 30.63, at a high 3-year percentile range.
Held by Invesco
Star Investor Invesco holds 2.66K shares of this stock.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
64.500
Target Price
+139.69%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of XOMA Royalty Corp is 6.82, ranking 48 out of 76 in the Media & Publishing industry. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 9.35M, representing a year-over-year increase of 29.93%, while its net profit experienced a year-over-year increase of 148.26%.
Score
Financials
8.22
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.57
Operational Efficiency
6.79
Growth Potential
5.42
Shareholder Returns
7.08
XOMA Royalty Corp's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of XOMA Royalty Corp is 7.13, ranking 53 out of 76 in the Media & Publishing industry. Its current P/E ratio is 30.63, which is 38.21% below the recent high of 42.33 and 223.48% above the recent low of -37.82.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 36/76
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of XOMA Royalty Corp is 8.50, ranking 4 out of 76 in the Media & Publishing industry. The average price target is 58.00, with a high of 104.00 and a low of 50.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
64.500
Target Price
+139.69%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
19
Total
8
Median
11
Average
Company name
Ratings
Analysts
XOMA Royalty Corp
XOMA
4
Roku Inc
ROKU
32
Paramount Global
PARA
26
Live Nation Entertainment Inc
LYV
25
TKO Group Holdings Inc
TKO
23
Paramount Skydance Ord Shs Class B
PSKY
21
1
2
3
4
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of XOMA Royalty Corp is 6.70, ranking 42 out of 76 in the Media & Publishing industry. Currently, the stock price is trading between the resistance level at 29.05 and the support level at 22.40, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
26.026
Sell
MA10
25.692
Sell
MA20
26.611
Sell
MA50
27.525
Sell
MA100
31.380
Sell
MA200
29.493
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of XOMA Royalty Corp is 5.00, ranking 33 out of 76 in the Media & Publishing industry. The latest institutional shareholding proportion is 67.32%, representing a quarter-over-quarter decrease of 1.28%. The largest institutional shareholder is The Vanguard, holding a total of 701.66K shares, representing 5.67% of shares outstanding, with 47.70% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BVF Partners L.P.
Morgan Stanley Investment Management Inc. (US)
Fidelity Management & Research Company LLC
BlackRock Institutional Trust Company, N.A.
Opaleye Management Inc.
Geode Capital Management, L.L.C.
Woodline Partners LP
State Street Investment Management (US)
Stonepine Capital Management, LLC
1
2
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Media & Publishing domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of XOMA Royalty Corp is 3.65, ranking 45 out of 76 in the Media & Publishing industry. The company's beta value is 0.86. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. XOMA Royalty Corp’s latest ESG disclosure leads the Media & Publishing industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
Score
Beta vs S&P 500 index
0.86
VaR
+6.03%
240-Day Maximum Drawdown
+37.92%
240-Day Volatility
+67.62%
Return
Best Daily Return
60 days
+9.96%
120 days
+9.96%
5 years
+21.08%
Worst Daily Return
60 days
-22.76%
120 days
-22.76%
5 years
-22.76%
Sharpe Ratio
60 days
-1.21
120 days
-0.51
5 years
+0.18
Risk Assessment
Maximum Drawdown
240 days
+37.92%
3 years
+44.63%
5 years
+63.69%
Return-to-Drawdown Ratio
240 days
+0.15
3 years
+0.11
5 years
-0.11
Skewness
240 days
-0.91
3 years
+0.28
5 years
+0.40
Volatility
Realised Volatility
240 days
+67.62%
5 years
+68.17%
Standardised True Range
240 days
+6.31%
5 years
+5.72%
Downside Risk-Adjusted Return
120 days
-55.35%
240 days
-55.35%
Maximum Daily Upside Volatility
60 days
+54.56%
Maximum Daily Downside Volatility
60 days
+67.08%
Liquidity
Average Turnover Rate
60 days
+0.48%
120 days
+0.38%
5 years
--
Turnover Deviation
20 days
+81.14%
60 days
+80.61%
120 days
+40.74%
Peer Comparison
Media & Publishing
XOMA Royalty Corp
XOMA
6.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Liberty Broadband Corp
LBRDK
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Nexstar Media Group Inc
NXST
8.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
TKO Group Holdings Inc
TKO
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
New York Times Co
NYT
8.29 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Imax Corp
IMAX
8.25 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
